@article{3191176,
    title = "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for
Prevention, Antithrombotic Therapy, and Follow",
    author = "Bikdeli, Behnood and Madhavan, Mahesh V. and Jimenez, David and Chuich, and Taylor and Dreyfus, Isaac and Driggin, Elissa and Der Nigoghossian, and Caroline and Ageno, Walter and Madjid, Mohammad and Guo, Yutao and Tang, and Liang V. and Hu, Yu and Giri, Jay and Cushman, Mary and Quere, Isabelle and and Dimakakos, Evangelos P. and Gibson, C. Michael and Lippi, Giuseppe and and Favaloro, Emmanuel J. and Fareed, Jawed and Caprini, Joseph A. and and Tafur, Alfonso J. and Burton, John R. and Francese, Dominic P. and Wang, and Elizabeth Y. and Falanga, Anna and McLintock, Claire and Hunt, Beverley and J. and Spyropoulos, Alex C. and Barnes, Geoffrey D. and Eikelboom, John and W. and Weinberg, Ido and Schulman, Sam and Carrier, Marc and Piazza, and Gregory and Beckman, Joshua A. and Steg, Gabriel and Stone, Gregg W. and and Rosenkranz, Stephan and Goldhaber, Samuel Z. and Parikh, Sahil A. and and Monreal, Manuel and Krumholz, Harlan M. and Konstantinides, Stavros V. and and Weitz, Jeffrey I. and Lip, Gregory Y. H. and Global COVID-19 and Thrombosis Collabo and ISTH and NATF and ESVM and ESC Working Grp Pulm and Ci",
    journal = "Journal of the American College of Cardiology",
    year = "2020",
    volume = "75",
    number = "23",
    pages = "2950-2973",
    publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",
    issn = "0735-1097, 1558-3597",
    doi = "10.1016/j.jacc.2020.04.031",
    abstract = "Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused
by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may
predispose patients to thrombotic disease, both in the venous and
arterial circulations, because of excessive inflammation, platelet
activation, endothelial dysfunction, and stasis. In addition, many
patients receiving antithrombotic therapy for thrombotic disease may
develop COVID-19, which can have implications for choice, dosing, and
laboratory monitoring of antithrombotic therapy. Moreover, during a time
with much focus on COVID-19, it is critical to consider how to optimize
the available technology to care for patients without COVID-19 who have
thrombotic disease. Herein, the authors review the current understanding
of the pathogenesis, epidemiology, management, and outcomes of patients
with COVID-19 who develop venous or arterial thrombosis, of those with
pre-existing thrombotic disease who develop COVID-19, or those who need
prevention or care for their thrombotic disease during the COVID-19
pandemic. (J Am Coll Cardiol 2020;75:2950-73) (c) 2020 by the American
College of Cardiology Foundation."
}